3/25
10:41 am
imvt
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. [Yahoo! Finance]
Low
Report
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. [Yahoo! Finance]
3/20
09:58 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Guggenheim.
3/20
08:05 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Bank of America Co. from $38.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Bank of America Co. from $38.00 to $33.00. They now have a "buy" rating on the stock.
3/19
12:38 pm
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
3/19
10:02 am
imvt
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Medium
Report
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
3/19
08:01 am
imvt
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies [Yahoo! Finance]
High
Report
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies [Yahoo! Finance]
3/19
07:45 am
imvt
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Medium
Report
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
3/18
04:32 pm
imvt
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Low
Report
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
3/10
12:19 pm
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Guggenheim.
3/10
11:11 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "mixed" rating re-affirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "mixed" rating re-affirmed by analysts at Jefferies Financial Group Inc..
3/5
07:43 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
3/3
08:06 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "hold" rating and a $20.00 price target on the stock.
High
Report
Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "hold" rating and a $20.00 price target on the stock.
2/10
09:02 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Guggenheim from $46.00 to $44.00. They now have a "buy" rating on the stock.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Guggenheim from $46.00 to $44.00. They now have a "buy" rating on the stock.
2/7
03:56 pm
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
2/6
07:10 am
imvt
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 [Yahoo! Finance]
High
Report
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 [Yahoo! Finance]
2/6
06:30 am
imvt
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
Medium
Report
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
2/1
05:58 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
1/24
01:34 pm
imvt
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
1/15
08:42 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Bank of America Co. from $48.00 to $45.00. They now have a "buy" rating on the stock.
Medium
Report
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Bank of America Co. from $48.00 to $45.00. They now have a "buy" rating on the stock.
1/14
08:30 am
imvt
Electronic Data Capture Redefined: Challenging the Norm with eSource Innovation, Upcoming Webinar Hosted by Xtalks
Low
Report
Electronic Data Capture Redefined: Challenging the Norm with eSource Innovation, Upcoming Webinar Hosted by Xtalks
1/13
08:00 am
imvt
Immunovant Announces $450 Million Private Placement
Low
Report
Immunovant Announces $450 Million Private Placement
1/3
08:07 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.